

Randomized Clinical Trials Actively Recruiting Patients to Evaluate Drug Treatments for NMO/SD *

Industry Sponsor	Clinical Trial Name	Clinical Trials.gov Code	Drug Name	Drug Type	Drug Target	Trial Status	Study Design	Chance of Placebo	Primary Outcome	Key Inclusion Criteria	Key Exclusion Criteria	Recruit Goal	Further Information
Alexion	PREVENT	NCT 1892345	Eculizumab	MAB	C5 Protein	Phase 3 Active	Random; Double masked; Add-on placebo control	33%	Time to Relapse	≥ 18 yrs; Sero +; ≥ 2 relapse prior year or 3 in prior 2 years	Rituximab prior 3 months; specific treatment history; see NCT code for details	132 Patients	Alexion.com
Chugai (Roche)	SAKura Star	NCT 02073279	SA237	MAB	IL-6 Receptor	Phase 3	Random; Double masked; Pure placebo control	33%	Time to Relapse	18–74 yrs; Sero + or –	Pregnant; see NCT code for details	90 Patients	Clinical-trials@chugai-pharm.com
MedImmune (AstraZeneca)	N-Momentum	NCT 02200770	Inebilizumab (MEDI-551)	MAB	CD19+ B Cells	Phase 2/3 Active	Random; Double masked; Pure placebo control	25%	Time to Relapse	≥ 18 yrs; Sero + or –; ≥ 1 relapse prior year or 2 in prior 2 years	Pregnant; Specific treatment history; see NCT code for details	212 Patients	MedImmune.com

KEY

ClinicalTrials.gov is a clinical trials information registry service of the U.S. National Institutes of Health
MAB = Monoclonal antibody (biologic) drug
Chance of placebo = statistical probability of being randomized into the placebo study group

**Listed in alphabetical order with no expressed or implied preference or recommendation to patients*